Therapeutic
The market for gastrointestinal (GI) disorder therapies is undergoing pivotal changes.
With this in mind, Scrip Reports brings you Gastrointestinal Disorders � New therapies for the new millennium, containing the very latest market information for GI treatments and providing a timely overview of major future trends.
Disease facts, treatment options, world market data, forecasts to 2002 and active research areas are supplied for each disorder in a clear, in-depth style. In addition, the report describes strengths and weaknesses of the key GI products and provides extensive information on drugs in R&D for each major GI disorder.
Gastrointestinal Disorders � New therapies for the new millennium covers individual therapeutic categories, with a particular focus on the major GI disorders, including gastroesophageal reflux disease (GERD); peptic ulcers; inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).
Also included in this report are detailed profiles of the top 17 players in the GI market.
PUBLISHED: October 2000
REF: BS1073E
PAGES: 180+
PRICE: £595/$1250/¥143,000
CONTENTS
LIST OF TABLES
LIST OF FIGURES
EXECUTIVE SUMMARY
ABBREVIATIONS AND GLOSSARY
CHAPTER 1 INTRODUCTION TO GASTROINTESTINAL
DISORDERS
1.1 Definition of gastrointestinal disorders
1.2 Diagnosis of GI disorders
1.2.1 Diagnostic criteria
1.2.2 Radiographic techniques
1.2.2.1 Barium meal
1.2.2.2 Barium enema
1.2.3 Endoscopic techniques
1.2.3.1 Oesophagoscopy
1.2.3.2 Gastroscopy
1.2.3.3 Upper GI endoscopy
1.2.3.4 Proctoscopy
1.2.3.5 Sigmoidoscopy
1.2.3.6 Colonoscopy
1.2.4 Other techniques
1.3 Types of GI disorders
1.3.1 Gastroesophageal reflux disease
1.3.2 Gastritis and GI ulcers
1.3.2.1 Gastritis
1.3.2.2 GI ulcers
1.3.2.3 Association between H. pylori and gastritis/peptic ulcers
1.3.2.4 Association between non-steroidal anti-inflammatory drugs
and gastritis/peptic ulcers
1.3.3 Inflammatory bowel diseases
1.3.3.1 Crohn's disease
1.3.3.2 Ulcerative colitis
1.3.4 Functional GI disorders
1.3.4.1 Irritable bowel syndrome
1.3.4.2 Functional (non-ulcer) dyspepsia
1.3.4.3 Functional constipation
1.4 Incidence and prevalence of GI disorders
1.4.1 Incidence and prevalence of gastroesophageal reflux disease
1.4.2 Incidence and prevalence of gastritis and GI ulcers
1.4.3 Incidence and prevalence of inflammatory bowel diseases
1.4.4 Incidence and prevalence of irritable bowel syndrome
1.5 The economic cost of GI disorders
1.5.1 Economic cost of gastroesophageal reflux disease
1.5.2 Economic cost of gastritis and GI ulcers
1.5.3 Economic cost of inflammatory bowel diseases
1.5.4 Economic cost of irritable bowel syndrome
1.6 The management of GI disorders
1.6.1 Gastroesophageal reflux disease management
1.6.1.1 Non-pharmacological treatment of gastroesophageal reflux
disease
1.6.1.2 Pharmacological treatment of gastroesophageal reflux
disease
1.6.2 Gastritis and peptic ulcer management
1.6.2.1 Non-pharmacological treatment of gastritis and peptic
ulcers
1.6.2.2 Pharmacological treatment of gastritis and peptic ulcers
1.6.3 Inflammatory bowel disease management
1.6.3.1 Non-pharmacological treatment of inflammatory bowel
diseases
1.6.3.2 Pharmacological treatment of inflammatory bowel diseases
1.6.4 Irritable bowel syndrome management
1.6.4.1 Non-pharmacological treatment of irritable bowel syndrome
1.6.4.2 Pharmacological treatment of irritable bowel syndrome
1.7 Conclusion
CHAPTER 2 GASTROINTESTINAL DRUGS ON THE
MARKET
2.1 Introduction
2.2 Marketed drugs for acid GI disorders
2.2.1 Acid-suppressing agents
2.2.1.1 Histamine H2 antagonists
2.2.1.2 Proton pump inhibitors
2.2.2 Acid neutralising agents and cytoprotectants
2.2.2.1 Antacids
2.2.2.2 Cytoprotectants
2.2.3 Prokinetic agents
2.2.4 H. pylori eradication therapies
2.3 Marketed drugs for inflammatory bowel diseases
2.3.1 Aminosalicylates
2.3.2 Corticosteroids
2.3.3 Immunomodulators
2.4 Marketed drugs for irritable bowel syndrome
2.4.1 Antispasmodics
2.4.2 Antidiarrhoeals
2.4.3 Alosetron
2.5 Conclusion
CHAPTER 3 GASTROINTESTINAL DRUGS IN
DEVELOPMENT
3.1 Introduction
3.2 Drugs in development for acid GI disorders
3.2.1 Acid-suppressing agents
3.2.1.1 Antigastrin-17
3.2.1.2 BY-112
3.2.1.3 CR-2945
3.2.1.4 Esomeprazole
3.2.1.5 H-335/25
3.2.1.6 IY-81149
3.2.1.7 Osutidine
3.2.1.8 Pibutidine
3.2.1.9 Tenatoprazole
3.2.1.10 YH-1885
3.2.2 Acid neutralising agents and cytoprotectants
3.2.2.1 DA-9601
3.2.2.2 Dosmalfate
3.2.2.3 Egualen sodium
3.2.2.4 NE-0080
3.2.3 Prokinetic agents
3.2.3.1 GM-611
3.2.3.2 JK-1085
3.2.3.3 Z-338
3.2.4 H. pylori eradication therapies
3.2.4.1 Helicide
3.2.4.2 H. pylori vaccine - Antex
3.2.4.3 H. pylori vaccine - Peptide Therapeutics
3.3 Drugs in development for inflammatory bowel disease
3.3.1 Biologic agents
3.3.1.1 BXT-51072
3.3.1.2 CDP-571
3.3.1.3 ICM3
3.3.1.4 Interleukin-10
3.3.1.5 LDP-02
3.3.1.6 Natalizumab
3.3.1.7 Thalidomide - Andrulis
3.3.1.8 Thalidomide - Celgene
3.3.2 Miscellaneous mechanisms of action
3.3.2.1 APC-2059
3.3.2.2 ATL-2502
3.3.2.3 OP-2000
3.3.2.4 Ridogrel
3.3.2.5 Tazofelone
3.4 Drugs in development for irritable bowel syndrome
3.4.1 Serotonergic modulators
3.4.1.1 CHF-17454
3.4.1.2 Cilansetron
3.4.1.3 E-3620
3.4.1.4 LY-315535
3.4.1.5 MKC-733
3.4.1.6 Norcisapride
3.4.1.7 Piboserod
3.4.1.8 Prucalopride
3.4.1.9 Renzapride
3.4.1.10 Tegaserod
3.4.2 Other mechanisms of action
3.4.2.1 Calcium polycarbophil
3.4.2.2 Dexloxiglumide
3.4.2.3 Fedotozine
3.4.2.4 SR-58611
3.5 Conclusion
CHAPTER 4 GASTROINTESTINAL DRUGS MARKET
INFORMATION
4.1 Introduction
4.2 Market value
4.2.1 World pharmaceutical sales
4.2.2 The gastointestinal market
4.3 Market structure
4.3.1 The market for acid disorder drugs
4.3.1.1 Acid suppressants
4.3.2 The market for inflammatory bowel disease drugs
4.3.3 The market for irritable bowel syndrome drugs
4.4 Market growth
4.4.1 Market growth for acid disorder drugs
4.4.1.1 Market growth for acid suppressants
4.4.2 Market growth for inflammatory bowel disease drugs
4.4.3 Market growth for functional GI disorder drugs
4.5 Market influences
CHAPTER 5 SELECTED COMPANY PROFILES
5.1 Abbott
5.1.1 Financial highlights
5.1.2 GI portfolio/pipeline
5.2 Alizyme plc
5.2.1 Agreements regarding GI therapies
5.2.2 Financial highlights
5.2.3 Gastrointestinal portfolio/pipeline
5.3 American Home Products Corporation
5.3.1 Agreements regarding GI therapies
5.3.2 Financial highlights
5.3.3 Gastrointestinal portfolio/pipeline
5.4 AstraZeneca
5.4.1 Agreements regarding GI therapies
5.4.2 Financial highlights
5.4.3 GI portfolio/pipeline
5.5 Altana/Byk Gulden
5.5.1 Agreements regarding GI therapies
5.5.2 Financial highlights
5.5.3 GI portfolio/pipeline
5.6 Axcan Pharma Inc
5.6.1 Agreements regarding GI therapies
5.6.2 Financial highlights
5.6.3 GI portfolio/pipeline
5.7 Axys Pharmaceutical Inc
5.7.1 Agreements regarding GI therapies
5.7.2 Financial highlights
5.7.3 GI portfolio/pipeline
5.8 Celltech Group plc
5.8.1 Financial highlights
5.8.2 GI portfolio/pipeline
5.9 Chugai Pharmaceutical Co Ltd
5.9.1 Agreements regarding GI therapies
5.9.2 Financial highlights
5.9.3 GI portfolio/pipeline
5.10 Eisai Co Ltd
5.10.1 Agreements regarding gastrointestinal therapies
5.10.2 Financial highlights
5.10.3 Gastrointestinal portfolio/pipeline
5.11 Glaxo Wellcome
5.11.1 Agreements regarding gastrointestinal therapies
5.11.2 Financial highlights
5.11.3 Gastrointestinal portfolio/pipeline
5.12 Eli Lilly
5.12.1 Agreements regarding GI therapies
5.12.2 Financial highlights
5.12.3 GI portfolio/pipeline
5.13 Neose Technologies Inc
5.13.1 Agreements regarding GI therapies
5.13.2 Financial highlights
5.13.3 GI portfolio/pipeline
5.14 Novartis Pharma AG
5.14.1 Financial highlights
5.14.2 GI portfolio/pipeline
5.15 SmithKline Beecham
5.15.1 Agreements regarding gastrointestinal therapies
5.15.2 Financial highlights
5.15.3 Gastrointestinal portfolio/pipeline
5.16 Solvay SA
5.16.1 Agreements regarding GI therapies
5.16.2 Financial highlights
5.16.3 GI portfolio/pipeline
5.17 Takeda
5.17.1 Agreements regarding GI therapies
5.17.2 Financial highlights
5.17.3 GI portfolio/pipeline
CHAPTER 6 DIRECTORY
REFERENCES
LIST OF TABLES
Table 1.1 The manifestations of gastroesophageal
reflux disease
Table 1.2 Classifications of gastritis
Table 1.3 Symptoms associated with peptic ulcers
Table 1.4 Symptoms of Crohn's disease
Table 1.5 Symptoms of ulcerative colitis
Table 1.6 Sub-classifications of ulcerative
colitis
Table 1.7 Symptoms associated with irritable
bowel syndrome
Table 1.8 Manning criteria for the diagnosis of
irritable bowel syndrome
Table 1.9 Rome I and Rome II criteria for the
diagnosis of IBS
Table 1.10 Rome criteria for the diagnosis of
functional dyspepsia
Table 1.11 Rome criteria for the diagnosis of
functional constipation
Table 1.12 Gastointestinal associated mortality
rates for selected countries
Table 1.13 Average length of hospital stay due
to GI disorders in selected countries
Table 1.14 Average length of hospital stay due
to peptic ulcer disease in selected countries
Table 1.15 Selected current gastroesophageal
reflux disease therapies on the market
Table 1.16 Examples of current antigastritis/ulcer
therapies on the market
Table 1.16 Examples of current anti-H. pylori
therapies on the market
Table 1.18 Drugs used in inflammatory bowel
disease by pharmacology
Table 1.19 Examples of current inflammatory
bowel disease therapies on the market
Table 1.20 Examples of current irritable bowel
syndrome therapies on the market
Table 2.1 Marketed histamine H2 antagonists
Table 2.2 Comparison of GI acid disorder drugs
Table 2.3 Marketed proton pump inhibitors
Table 2.4 Examples of prescription antacids and
cytoprotectants
Table 2.5 Marketed prokinetic drugs
Table 2.6 Current anti-H. pylori therapies on
the market
Table 2.7 Marketed aminosalicylates used in
inflammatory bowel disease
Table 2.8 Characteristics and formulations for
selected mesalazine preparations
Table 2.9 Marketed corticosteroids used in
inflammatory bowel disease
Table 2.10 Selected marketed drugs used in
irritable bowel syndrome therapy
Table 3.1 Acid-suppressing drugs in
development
Table 3.2 Cytoprotectants in development
Table 3.3 Prokinetic agents in development
Table 3.4 H. pylori eradication therapies in
development
Table 3.5 Biologic inflammatory bowel disease
therapies in development
Table 3.6 Non-biologic inflammatory bowel
disease therapies in development
Table 3.7 Serotonergic modulators in development
for irritable bowel syndrome
Table 3.8 Non-serotonergic agents in development
for irritable bowel syndrome
Table 4.1 World pharmaceutical sales, 1999
Table 4.2 Top 10 major therapeutic categories
Table 4.3 Leading GI companies by acid disorder
agents, 1999
Table 4.4 Estimated worldwide sales of selected
branded histamine H2 antagonists, 1999
Table 4.5 Estimated worldwide sales of proton
pump inhibitors, 1999
Table 5.1 Abbott's financial results, 1998-2000
(1st quarter)
Table 5.2 Abbott's sales by region, 1998-1999
Table 5.3 Abbott's healthcare sales by business
area, 1998-1999
Table 5.4 Alizyme's financial results, 1998-2000
Table 5.5 American Home Products' financial
results, 1998-2000 (1st quarter)
Table 5.6 American Home Products' sales by
region, 1998-1999
Table 5.7 American Home Products' healthcare
sales by business segment, 1998-2000
Table 5.8 AstraZeneca's financial results, 1998-2000
(1st quarter)
Table 5.9 AstraZeneca's sales by region, 1998-2000
(1st quarter)
Table 5.10 AstraZeneca's healthcare sales by
therapeutic area, 1998-1999
Table 5.11 AstraZeneca's sales by major
pharmaceutical product, 1998-1999
Table 5.12 Altana's financial results, 1998-2000
(1st quarter)
Table 5.13 Altana's sales by region, 1998-2000 (1st
quarter)
Table 5.14 Altana's healthcare sales by
therapeutic area, 1998-1999
Table 5.15 Altana's sales by major
pharmaceutical product, 1999
Table 5.16 Axcan's financial results, 1997-1999
Table 5.17 Axys' financial results 1998-2000
Table 5.18 Celltech's proforma financial results,
1998-1999
Table 5.19 Chugai's financial results, 1998-2000
Table 5.20 Chugai's sales by region, 1998-2000
Table 5.21 Eisai's financial results, 1998-2000
Table 5.22 Eisai's leading domestic
pharmaceutical products, 1999-2000
Table 5.23 Glaxo Wellcome's financial results,
1998-2000 (1st quarter)
Table 5.24 Glaxo Wellcome's sales by region,
1998-1999
Table 5.25 Glaxo Wellcome's healthcare sales by
therapeutic area, 1998-1999
Table 5.26 Glaxo Wellcome's sales by major
pharmaceutical product, 1998-1999
Table 5.27 Eli Lilly's financial results, 1998-2000
(1st quarter)
Table 5.28 Eli Lilly's leading product sales,
1998-1999
Table 5.29 Neose's financial results, 1998-2000
Table 5.30 Novartis' financial results, 1998-2000
(1st quarter)
Table 5.31 Novartis' group sales by major
regions, 1998-1999
Table 5.32 Novartis' sales by therapeutic area,
1998-2000 (1st quarter)
Table 5.33 Novartis' sales by major
pharmaceutical product, 1999
Table 5.34 SmithKline Beecham's financial
results, 1998-2000 (1st quarter)
Table 5.35 SmithKline Beecham's sales by
business section, 1998-1999
Table 5.36 SmithKline Beecham's sales by
therapeutic sector, 1998-1999
Table 5.37 Solvay's financial results, 1998-1999
Table 5.38 Solvay's top six leading products,
1999
Table 5.39 Takeda's financial results, 1998-2000
Table 5.40 Takeda's sales by region, 1999-2000
LIST OF FIGURES
Figure 1.1 A schematic of the GI tract
Figure 1.2 Prevalence of upper GI symptoms in
selected developed nations
Figure 1.3 Prevalence of upper GI symptoms by
age
Figure 1.4 Incidence of heartburn in the US per
1,000 population, 1996
Figure 1.5 Incidence of peptic ulcers in the US
per 1,000 population, 1996
Figure 1.6 Incidence of irritable bowel syndrome
in the US per 1,000 population, 1996
Figure 2.1 The sites of action of certain acid disorder drugs
Figure 3.1 Percentage of erosive oesophagitis
patients healed with esomeprazole or omeprazole
Figure 3.2 Percentage of patients with
intragastric pH above 4
Figure 4.1 Pharmaceutical sales for 12 key
markets in for the 12 months to December 1999
Figure 4.2 Leading companies in the
gastrointestinal market
Figure 4.3 Gastrointestinal acid disorder
products market by category
Figure 4.4 Market share of acid suppressants by
category
Figure 4.5 Market share of proton pump
inhibitors, 1999
Figure 4.6 Acid suppressant market by
geographical region, 1999
Figure 4.7 Proton pump inhibitor and H2
antagonists markets by geographical region, 1999
Figure 4.8 Market trends for the GI products
market, projected to 2002
Figure 4.9 Market trends for the GI acid
disorder products market, projected to 2002
Figure 4.10 Market trends for cytoprotectants
and acid neutralising products, projected to 2002
Figure 4.11 Market trends for the H2 antagonist,
projected to 2002
Figure 4.12 Market trends for the proton pump
inhibitor sales, projected to 2002
Figure 4.13 Market trends for inflammatory bowel
disease therapies, projected to 2002
Figure 4.14 Market trends for anti-TNF-alpha
agents, projected to 2002
Figure 4.15 Market trends for functional GI
disorder drugs, projected to 2002
Figure 4.16 Market trends for irritable bowel
syndrome drugs, projected to 2002
Figure 4.17 Market trends for serotoninergic
modulators, projected to 2002
EXECUTIVE SUMMARY
'This is an exciting time in gastroenterology
when so many opportunities for new diagnostic tests and
treatments are opening up.'
Sir Leslie Turnberg, President of the British Society of
Gastroenterology, March 2000.
Gastrointestinal (GI) disorders are the most common ailments in the industrialised world and nearly everyone will be affected by a GI disorder during the course of his or her lifetime. GI disorders are a group of conditions that affect the digestive system. These can range from something as innocuous as a mild stomach upset to serious conditions, such as peptic ulcer disease or Crohn's disease.
In the industrialised world, GI disorders can affect up to 40% of
the population and in the US alone, more than 95 million people
are believed to experience some form of GI disorder, with over 10
million people hospitalised each year due to GI complications.
Epidemiological data for the developing world is less well
documented but evidence suggests that non-infectious disease-related
GI disorders are becoming more prevalent.
GI disorders encompasses a wide spectrum of complex diseases and
symptoms. These include the occasional discomfort of heartburn to
debilitating inflammatory conditions such as Crohn's disease and
ulcerative colitis. This report will focus on the most important
disease categories within GI disorders. This will include
discussions on the management of gastroesophageal reflux disease
(GERD), gastritis and peptic ulcer disease, inflammatory bowel
diseases (IBD) and functional GI disorders such as irritable
bowel syndrome (IBS).
The GI market is expected to undergo a state of flux as the world's
best-selling product, AstraZeneca's antiulcerant, omeprazole (Losec),
comes off patent around the world in 2001-2004. Losec accounts
for approximately 30% of the global antiulcerant market. The loss
of patent of such a high profile product will impact the whole
market for prescription GI drugs.
Chapter 1 introduces the major GI disorders with in-depth coverage of the definitions, pathogenesis and the therapeutic options available for GI acid disorders (GERD, gastritis and peptic ulcer disease), IBD (Crohn's disease and ulcerative colitis) and functional GI disorders (functional dyspepsia and IBS). GERD is the most common of the serious GI disorders. Current estimates suggest that 21-40% of people suffer symptoms of GERD and in the US 35-40% of the adult population suffer heartburn at least once a month. Peptic ulcer disease has a prevalence of 5-10% in developed countries and is still one of the leading causes of hospitalisation. The American College of Gastroenterology estimates that 20-25 million people in the US currently suffers from peptic ulcer disease or will develop an ulcer in their lifetime. The extent of these acid disorders places an enormous burden on both national health systems and the individuals who suffer. Out-of-pocket expenses for people with GI disorders are normally higher when compared with patients with other chronic problems such as diabetes, due to the greater use of self-medication by people affected by GI disorders.
Functional GI disorders are also extremely common and can affect
23-41% of the population in developed nations. Up to 20% of the
adult population in developed countries is estimated to be
affected by IBS, one of the main functional disorders, and in the
US, 1 in 5 of the population are thought to suffer from the
condition. Moreover, between 60-70% of IBS sufferers are female.
Whilst IBS is not life-threatening, its causes immense suffering
and discomfort to those affected by the condition and it is one
of the leading causes of work absenteeism. IBD is currently one
of the least common GI disorders but it is increasing in
incidence. The two forms of IBD, Crohn's disease and ulcerative
colitis, have similar characteristics of relapse and remission.
The chronic and incurable nature of IBD makes the disease an
important consideration in the spectrum of GI disorders.
Many of the drugs used to treat GI disorders are mature products.
However, a number of new agents have recently been introduced
that have exciting market potential.
Chapter 2 will review the current marketed prescription drugs in the GI sector, with an emphasis on strengths and weaknesses of agents with strong market presence and new introductions to the GI market. Self-medication also plays an important role in the market for GI therapies, particularly agents used in the treatment of acid disorders. Prescription drugs have to compete with the numerous products available over-the-counter, which are also aimed at relieving the symptoms of the major GI disorders. However, whilst this crowded market is extremely competitive, the sheer number of potential consumers makes this therapy group highly lucrative. Increased patient awareness has also increased the number of patients seeking medical advice with a subsequent rise in the use of prescription-only-medicines.
The acid disorders segment is by far the largest in the GI
category and acid suppression drugs, such as the histamine H2
antagonists and proton pump inhibitors, are the mainstay of
gastric acid-related GI disorders In particular, the proton pump
inhibitors represent a multi-billion dollar market. The PPIs have
shown tremendous growth year on year for the past 9 years but
their position is under threat with the impending loss of patent
protection for the category's most successful agent, AstraZeneca's
omeprazole (Losec/Prilosec). The more mature H2 antagonists have
struggled to compete with the proton pump inhibitors and there
has been a move towards the OTC market for some of the more
mature products.
Many of the agents used to alleviate the symptoms of functional
GI disorders are also available as OTC-products, especially
laxative and antidiarrhoeals drugs. However, the current therapy
for IBS, which has multiple symptoms, is rather limited. Glaxo
Wellcome's new serotoninergic modulator, alosetron (Lotronex),
represents a new force in the treatment of IBS. The product has
the potential to control many of the symptoms of diarrhoea-predominant
IBS and is predicted to be a success in this field.
The agents used to treat IBD are established drugs, with
indications for various other inflammatory or infective disorders.
However, the introduction of Centocor's antitumour necrosis
factor-alpha monoclonal antibody, infliximab (Remicade), has
caused excitement within the medical profession. Remicade's novel
mechanism of action is predicted to advance the treatment of
Crohn's disease.
The industry has benefited from major scientific advances the GI
disorders field, which has helped provide a greater understanding
of the various GI disorders. The pathogenesis of GERD, peptic
ulcer diseases, IBD and IBS is now better understood and this has
helped to select new targets for disease treatment. In addition,
the GI sector has embraced the new biotechnologies as important
tools in the development of innovative new drugs.
Chapter 3 provides a thorough review of all
the latest developments in the GI therapeutic category. The
important drug candidates will be previewed and their market
potential assessed. In the IBS and IBD therapeutic categories,
the launch of innovative novel treatments has led the shift away
from the 1traditional targets. The current R&D focus has now
moved towards the concept of the 'brain-gut' axis as a target for
treating IBS and in particular the involvement of the serotonin (5-HT)
neurotransmitter pathway. Similarly, the search for more
effective IBD drugs has led to the development of biologic agents.
The term 'biologic agent' is often used to describe molecules
that have been designed to target specific sites or components in
the immune response cascade. Biologic agents have been a major
innovation in the treatment of IBD. Novel biologic agents in
development include recombinant cytokines, recombinant anti-adhesion
molecules, antisense agents and humanised monoclonal antibodies.
New target sites include antitumour necrosis factor alpha (TNF-alpha),
intercellular adhesion molecule (ICAM), and the transcription
factors, nuclear factor kappa-B and the alpha-4 beta-7 protein.
In the acid disorder category, the most important agent in
development is AstraZeneca's new PPI, esomeprazole (Nexium).
There are a lot of expectations for Nexium and its potential will
be fully assessed.
Such is the extent of this group of conditions that the market
value for the GI therapeutic sector has been consistently one of
the largest, second only to sales of cardiovascular products.
Chapter 4 provides a valuable insight into
the present and future status of this lucrative market, which is
currently valued at $26-28 billion worldwide.
Finally, the major players and companies with potential in the GI
sector will be profiled in
Chapter 5. The profiles will include a review
of each companies core products and GI portfolio/pipelines.
1 Note: Definition of GERD: reflux of gastric contents into the oesophagus. Erosive oesophagatis is a distinct condition/symptom due to GERD.
© PJB Publications Ltd. 2000 All rights reserved. |